An Official Website of the United States Government
Company Information:
Name:
XCYTE THERAPIES, INC.
Address:
XCYTE THERAPIES, INC.
2203 AIRPORT WAY S, STE 300
SEATTLE, WA 98134
2203 AIRPORT WAY S, STE 300
SEATTLE, WA 98134
Located in HUBZone:
No
Woman-Owned:
No
Minority-Owned:
No
URL:
N/A
Phone:
(206) 328-7250
Award Totals:
Award List:
AUTOLOGOUS T CELL THERAPY FOR B-CLL
Award Year / Program / Phase:
1999 / SBIR / Phase I
Agency:
HHS
Principal Investigator:
Mark L. Bonyhadi
Award Amount:
$157,022.00
Abstract:
Not Available In order to be used in future infrared countermeasures systems, the cost of current diode pumped solid state lasers and mid-infrared parametric oscillators must be reduced and the size of the laser head must be significantly reduced. The proposed Phase I research will develop an… More
Autologous T Cell Therapy for CLL
Award Year / Program / Phase:
2003 / SBIR / Phase I
Agency:
HHS
Principal Investigator:
Mark W. Frohlich
Award Amount:
$0.00
Abstract:
DESCRIPTION (provided by applicant): Xcyte Therapies has developed a process ("Xcellerate") for the ex vivo activation and expansion of T cells using magnetic beads coated with antibodies to CD3 and CD28. Xcellerated T Cells from patients with CLL demonstrate an enhanced T cell repertoire, and the… More
Autologous T Cell Therapy for CLL
Award Year / Program / Phase:
2003 / SBIR / Phase II
Agency:
HHS
Principal Investigator:
Mark W. Frohlich
Award Amount:
$1,167,553.00
Abstract:
DESCRIPTION (provided by applicant): Xcyte Therapies has developed a process ("Xcellerate") for the ex vivo activation and expansion of T cells using magnetic beads coated with antibodies to CD3 and CD28. Xcellerated T Cells from patients with CLL demonstrate an enhanced T cell repertoire, and the… More